OBJECTIVE: This study aimed to evaluate the efficacy and toxicity of proton beam therapy combined with cisplatin intra-arterial infusion via a superficial temporal artery as treatment for maxillary sinus carcinoma. METHODS: Twenty-six patients with confirmed maxillary sinus carcinoma were enrolled in this study from May 2009 to April 2011. Patients underwent proton beam therapy and intra-arterial infusion chemotherapy with cisplatin. RESULTS: The median total dose was 70.4 GyE per 32 fractions, and the median dose of cisplatin was 300 mg/body for six cycles of intra-arterial infusion. The 3-year overall survival rate was 58% for all patients (n = 26), 58% for patients with stage T4 disease (n = 12), 57% for patients with <Stage T3 disease (n = 14), 66% for patients with squamous cell carcinoma (n = 15) and 45% for patients with non-squamous cell carcinoma (n = 11). Two patients developed non-hematologic side effects such as Grade 3 radiation dermatitis, one developed osteonecrosis and one developed brain necrosis. Ocular/visual problems occurred in three patients, which included Grade 4 retinopathy and Grade 3 cataract in one and two patients, respectively. CONCLUSIONS: Proton beam therapy combined with cisplatin intra-arterial infusion administered via a superficial temporal artery appears to be safe and effective for maxillary sinus carcinoma.
OBJECTIVE: This study aimed to evaluate the efficacy and toxicity of proton beam therapy combined with cisplatin intra-arterial infusion via a superficial temporal artery as treatment for maxillary sinus carcinoma. METHODS: Twenty-six patients with confirmed maxillary sinus carcinoma were enrolled in this study from May 2009 to April 2011. Patients underwent proton beam therapy and intra-arterial infusion chemotherapy with cisplatin. RESULTS: The median total dose was 70.4 GyE per 32 fractions, and the median dose of cisplatin was 300 mg/body for six cycles of intra-arterial infusion. The 3-year overall survival rate was 58% for all patients (n = 26), 58% for patients with stage T4 disease (n = 12), 57% for patients with <Stage T3 disease (n = 14), 66% for patients with squamous cell carcinoma (n = 15) and 45% for patients with non-squamous cell carcinoma (n = 11). Two patients developed non-hematologic side effects such as Grade 3 radiation dermatitis, one developed osteonecrosis and one developed brain necrosis. Ocular/visual problems occurred in three patients, which included Grade 4 retinopathy and Grade 3 cataract in one and two patients, respectively. CONCLUSIONS: Proton beam therapy combined with cisplatin intra-arterial infusion administered via a superficial temporal artery appears to be safe and effective for maxillary sinus carcinoma.